May 10
Current report
8-K
Financial results
GOSS · Gossamer Bio, Inc. · Documents
$9.28
-0.17 (-1.80%)
At close · Nov 3
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company's existing cash and cash equivalents are not sufficient to fund operating plans for at least one year from the issuance date of these financial statements. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$57.75M
Shares
6.11M
Volume · Nov 3
139.45K
Avg daily vol (38 sessions)
273.69K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2022
May 10
Quarterly report
10-Q
FY2022 Q1, ended Mar 31
Quarterly report for FY2022 Q1
Net loss $57.79M
Diluted EPS -$0.76
Apr 27
Proxy statement
DEF 14A
Meeting Jun 9, 2022
Proxy statement
Apr 27
Proxy statement
DEFA14A
Proxy statement
Apr 25
Current report
8-K
Financial results, Other events
Mar 3
Earnings call
Q4 2021 earnings call
Mar 3
Current report
8-K
Financial results
Mar 3
Mar 3
Registration statement
S-3ASR
Registration statement
2021
Nov 8
Earnings call
Q3 2021 earnings call
Nov 8
Current report
8-K
Financial results
Nov 8
Quarterly report
10-Q
FY2021 Q3, ended Sep 30
Quarterly report for FY2021 Q3
Net loss $60.25M
Diluted EPS -$0.80
Oct 12
Current report
8-K
Events of Oct 11
Regulation FD disclosure, Other events
Sep 21
Current report
8-K
Events of Sep 16
Director or officer change, or executive pay
Aug 9
Earnings call
Q2 2021 earnings call
Aug 9
Current report
8-K
Financial results
Aug 9
Quarterly report
10-Q
FY2021 Q2, ended Jun 30
Quarterly report for FY2021 Q2
Net loss $59.83M
Diluted EPS -$0.80
Jun 14
Current report
8-K
Events of Jun 9
Director or officer change, or executive pay, Shareholder vote results
May 6
Current report
8-K
Financial results
May 6
Quarterly report
10-Q
FY2021 Q1, ended Mar 31
Quarterly report for FY2021 Q1
Net loss $57.64M
Diluted EPS -$0.78
Apr 27
Proxy statement
DEF 14A
Meeting Jun 9, 2021
Proxy statement
Apr 27
Proxy statement
DEFA14A
Proxy statement
Apr 20
Current report
8-K
Events of Apr 17
Director or officer change, or executive pay
Feb 26
Feb 25
Earnings call
Q4 2020 earnings call
Feb 25
Current report
8-K
Financial results
2020
Nov 17
Current report
8-K
Events of Nov 16
Director or officer change, or executive pay
Nov 10
Earnings call
Q3 2020 earnings call
Nov 10
Current report
8-K
Financial results
Nov 10
Oct 13
Current report
8-K
Regulation FD disclosure, Other events
Aug 11
Current report
8-K
Financial results
Aug 11
Jul 2
Current report
8-K
Entered into a material agreement, New debt or off-balance-sheet obligation
Jun 18
Current report
8-K
Events of Jun 17
Shareholder vote results
May 21
Current report
8-K
Events of May 18
Entered into a material agreement, New debt or off-balance-sheet obligation, Other events
May 12
Earnings call
Q1 2020 earnings call
May 12
Current report
8-K
Financial results
May 12
Apr 27
Proxy statement
DEF 14A
Meeting Jun 17, 2020
Proxy statement
Apr 27
Proxy statement
DEFA14A
Proxy statement
Apr 10
Registration statement
S-3ASR
Registration statement
Mar 24
Current report
8-K
Financial results
Mar 24
Jan 13
Current report
8-K
Regulation FD disclosure
Showing 101–145 of 145 documents
Key facts
CIK
1728117
CUSIP
38341P201
13F (30d)
20 filings
13 filers
Visit website
Investor relations